Drug Trial Radar · NCT00980109
Long Term Influenza Prophylaxis With Inhaled Zanamivir or Oral Oseltamivir
Last checked: Nov 20, 2026Latest source record: Sep 22, 2010 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
390
Actual
Start
Sep 2009
Primary completion
Sep 2010
Study completion Sep 2010
Sponsor
- Lead sponsor
- University of OxfordAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Institute of Allergy and Infectious Diseases (NIAID)
- First posted
- Sep 18, 2009
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 20 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a multicenter, randomised, four arms placebo controlled study to evaluate the safety and tolerability of 10 mg inhaled zanamivir once a day and 75 mg oseltamivir capsule orally once a day relative to placebo over 16 weeks (112 days). Enrolled subjects will be randomly assigned to 2:1:2:1 ratio (active oseltamivir: placebo: active zanamivir: placebo) on one of the four study treatment groups. It is hypothesized that oseltamivir and zanamivir will protect participants from becoming infected with influenza.
Conditions
- Influenza
Interventions
active oseltamivirDrug
Oseltamivir capsules (75 mg per capsule), one capsule daily by mouth (PO) for 112 days. The dose should be administered at approximately the same time each day.
placebo capsuleDrug
Placebo capsules, one capsule daily for 112 days. The capsule should be administered at approximately the same time each day.
zanamivir for inhalationDrug
Zanamivir for inhalation, (5 mg per inhalation), two inhalations, once daily using a ROTADISK/DISKHALER for 112 days. The dose should be administered at approximately the same time each day.
placebo for inhalationDrug
Placebo (lactose powder), two inhalations, once daily using a ROTADISK/ DISKHALER for 112 days. The dose should be administered at approximately the same time each day.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of subjects who withdraw from the study because of serious adverse events (SAEs) that are possibly or probably or definitely related to the study drugTime frame: 1 year
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Hospital for Tropical Diseases
Bangkok, Thailand
Faculty of Medicine Siriraj Hospital
Bangkok, Bangkoknoi, Thailand
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.